Editorial: Innovative value-based medicine: lessons from China's and APAC's healthcare evolution, volume II Jing Yuan, Xiangxiang Jiang, Gang Lv, Z. Kevin Lu Value-based medicine (VBM) has moved from a broad aspiration to a concrete reform agenda: health systems are increasingly asked to pursue measurable outcomes rather than clinical activity. The core literature frames value as a relationship among outcomes, patient experience, and resources (–), while the Consolidated Health Economic Evaluation Reporting Standards (CHEERS), standard economic-evaluation methods, and health technology assessment guidance show how evidence can be translated into transparent choices (–). These tools, however, must be embedded in local institutions rather than applied as abstract checklists. This transition is especially relevant for China and the Asia-Pacific region, where population aging, chronic disease, expensive technologies, and coverage commitments converge. Volume II illustrates that value is not produced by one instrument. It emerges through payment design, price negotiation, resource allocation, hospital operations, outpatient experience, post-acute care, and public health governance. The Research Topic is therefore best read as an evidence base for policy learning and refinement: reforms can improve access and efficiency, but they can also create new inequities and measurement gaps if implementation is not watched closely. This matters because the same policy may look efficient in aggregate yet operate differently across hospitals, consumers, and patient groups. Payment reform is the clearest thread (). Xu X. et al. show that payment based on curative-effect value for traditional Chinese medicine (TCM)-dominant anorectal diseases can reduce cost and length of stay while restoring use of TCM-specific diagnostic and treatment services. Sheng et al. report that Diagnosis-Intervention Packet (DIP) payment for type 2 diabetes mellitus lowered hospitalization costs and length of stay but shifted out-of-pocket burden toward resident basic medical insurance enrollees and TCM hospital users. Wu et al. add a warning from Diagnosis-Related Group (DRG) payment data: high-margin cases were more likely to be low-value hospitalizations, suggesting that bundled payment may simply move waste rather than remove it. Zheng et al. find that clinical pathway-based single disease payment for hysterectomy reduced expenses, shortened stays, increased minimally invasive surgery, and lowered complications. Yang et al. complete the implementation picture by showing that clinicians' attitudes, not knowledge alone, shape diagnosis-based payment practice. These studies favor payment models with equity guardrails, case-mix surveillance, and clinician engagement. They also show why average savings should never be interpreted without distributional and behavioral evidence. A second group addresses access to medicines and innovation (). Xie et al. find that provincial pooling of basic medical insurance increased inpatient use and spending without eliminating pro-rich inequality, so financial integration must be linked to resource redistribution. Xu H. et al. and Zhu et al. examine National Drug Price Negotiation from the firm side. Their findings suggest that negotiation access can stimulate research and development investment and patenting, particularly when market signals, subsidies, firm size, and market power support innovation. This challenges the simple claim that price negotiation necessarily discourages industry investment. Yet patient access remains unfinished. Yao et al. show that innovative anticancer medicines were less available and affordable than essential or generic medicines. Jiang et al. report that lecanemab provides better value than aducanumab but is not cost-effective against standard care at current prices. Liu et al. and Sun et al. further show that multidimensional assessment methods can help compare devices and TCM products when evidence, safety, patient value, and budget impact must be balanced. Delivery capacity is another value determinant (). Huang et al. estimate generally high primary healthcare efficiency in China, but regional imbalance and projected outpatient demand growth suggest continued pressure on grassroots services. Lyu reaches a similar conclusion by showing spatial dependence, path dependence, and club formation in resource allocation efficiency; weaker regions may not converge without targeted support. Patient-centered implementation is equally important. Chin et al. describe a Singapore General Hospital framework that operationalizes value-based care for outpatient conditions through scoping, outcome selection, baseline assessment, and improvement planning. Wei et al. develop a patient-centered outpatient satisfaction tool and identify the physician-patient relationship, waiting-order management, and service quality as major drivers. These papers remind us that VBM cannot be implemented only through reimbursement rules. It also requires data systems, workflow redesign, institutional learning, and patient-reported measures that capture what care actually feels like. In hospital-centered health systems, this delivery perspective is essential for avoiding narrow, payer-only definitions of value. Post-acute and environmental studies extend the boundaries of value (). Zuo, Zhou, Do, et al. argue in Part 1 that home infusion therapy and home health services could address aging, antimicrobial resistance, long infusion needs, and hospital crowding in China. Zuo, Zhou, Huynh, et al. in Part 2 move from demand to execution, emphasizing accreditation, sterile compounding, technology integration, workforce training, and value-aligned reimbursement. Together, these reviews shift the discussion from hospital episodes to longitudinal care delivered where patients live. Tang et al. broaden the frame further by estimating health-economic burdens from fine particulate matter (PM2.5) and ozone (O3) across Chinese regions from 2013 to 2023. The simultaneous decline in PM2.5-related burden and rise in O3-related mortality shows that value is also created through prevention outside clinical encounters. For VBM, the denominator should include avoidable hospital days, delayed institutionalization, exposure risk, and population-level prevention rather than hospital throughput alone. Taken together, these studies offer several important implications. First, cost containment should not be conflated with value; savings matter only when quality, equity, and outcomes are preserved. Second, price and payment reforms require transparent assessment methods and post-implementation surveillance. Third, VBM in China and the Asia-Pacific region should remain pluralistic: TCM-dominant services, oncology and dementia medicines, medical devices, outpatient pathways, home-based care, and environmental health require distinct evidence standards and operational tools. Fourth, implementation capacity has value in itself. Policies that appear efficient nationally may fail locally when clinicians are unconvinced, data systems are fragmented, or disadvantaged regions lack resources. These constraints are central, not peripheral, to whether evidence-based reform translates to durable practice. Volume II advances the field by presenting VBM as an iterative cycle of measurement, incentive design, learning, and correction. Its practical agenda is clear: define outcomes that matter to patients and society, pay for appropriate care, assess technologies transparently, protect equity, and revise policies when real-world consequences emerge.